Cellply secures €2.34m non-dilutive grant funding from the European Commission for a novel precision oncology diagnostic platform

A new diagnostic system defines patient-specific efficacy of anticancer drugs by testing in-vitro drug response of patient’s tumor cells

Bologna (Italy) – May 24, 2018 – Cellply, an Italian medtech company specialized in in-vitro diagnostic systems aiming at supporting personalized oncology treatment, announced to have been selected by the European Commission among the winners of the prestigious Horizon 2020 – SME Instrument program, obtaining €2.3m funding for the Oncosmart project. Cellply achieved this result after a highly competitive selection process which resulted in only 64 European companies funded among 1280 applicants. The grant received by Cellply is the largest one among the 9 Italian companies funded in the last SME Instrument call and one of the largest at EU level since the start of the SME instrument program in 2014.

Today anticancer drugs are beneficial to a small number of patients, with failure rates up to 75%. The use of DNA sequencing-based precision medicine tests often produces limited improvements due to their low accuracy when used to predict treatments response. Moreover, 60-70% of the patients do not feature known genetic mutations. Cellply developed the first standardized and automated system able to predict patients’ response to more than 10 therapies tested in parallel in just 24 hours and with high accuracy. Cellply’s test results are independent from the genetic makeup of the patient or its tumor. It evaluates the in-vitro ability of anticancer drugs to affect the activity of tumor cells and induce their death. This technology is able to evaluate anticancer drug combinations at different dosing schemes and future immunotherapies testing is planned. Cellply’s platform will also support clinical trials identifying the most suitable therapeutic indications for drugs under investigation and stratifying patients by identifying non-responders in advance.

«Cellply has a great opportunity to make a pivotal change in cancer care. We are very honored to receive this recognition that will accelerate the development of our platform and its clinical validation, by involving an important network of European oncology institutes» reports Massimo Bocchi, President and CEO at Cellply. «The results we obtained during initial clinical tests on acute leukemias showed the possibility to predict the action of anticancer drugs before they are administered to patients, with a precision beyond our expectations. Our goal is to make cancer treatment individualized and allow each patient to receive the most suitable drugs selected through a predictive test run on his own tumor cells».

About Cellply
Cellply, based in Bologna (Italy), was founded in 2013 by two engineers, Prof. Roberto Guerrieri from the University of Bologna and Massimo Bocchi. In 2014 the company started the development of an in-vitro diagnostic platform allowing to isolate a tiny amount of live tumor cells sampled from patients within 20,000 microwells and analyze the action of multiple drugs in parallel by means of proprietary algorithms to predict the response of the patient to candidate drug therapies. Cellply has already secured equity funding from Italian investors, namely the business angels from Italian Angels for Growth association, Atlante Seed venture capital fund managed by Indaco Venture Partners Sgr and Ingenium II Fund from Emilia Romagna Region managed by Meta Ventures. For more information, please visit www.cellply.com

 

Press contact: press@cellply.com

Download press release (English) (Italian)

Cellply selected as finalist at Lyfebulb Oncology Award

MONACO, PRINCIPALITY OF MONACO, NEW YORK, NY, and BOLOGNA, ITALY, March 1, 2018:

Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, have announced today that Cellply has been selected as one the eleven finalist companies for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. The Lyfebulb-Helsinn Innovation Summit & Award final event will be hosted on 26-27 March 2018, by Lyfebulb and Helsinn at the Monte-Carlo Bay Hotel and Resort, in Monaco, Principality of Monaco.

Read the full story here

Cellply abstract accepted at the AACR 2018 Annual Meeting

Bologna (Italy), 4 February 2018

Cellply will present results of clinical testing activities on Acute Myeloid Leukemia patients at the American Association for Cancer Research (AACR) 2018 Annual Meeting, taking place April 14-18 in Chicago.

Results of the study, conducted in collaboration with haematologists and researchers at the Sant’Orsola-Malpighi Polyclinic in Bologna, show the high accuracy obtained with Cellply’s platform in predicting standard therapy outcome.

Title: Lab-on-a-chip-based in-vitro functional profiling proves to be effective in predicting therapy outcome in AML patients
Authors: Laura Rocchi, Andrea Faenza, Laura Rambelli, Viviana Guadagnuolo, Giovanni Marconi, Giorgia Simonetti, Cristina Papayannidis, Antonella Padella, Nicola Pecorari, Luca Giulianelli, Dario Biscarini, Giovanni Martinelli, Roberto Guerrieri and Massimo Bocchi
Abstract ID: 3613
Date/Time: Tuesday Apr 17, 2018 8:00 AM – 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 25
Session Category: Clinical Research
Session Title: Biomarker Discovery 4

Link to abstract

View poster online

Cellply and Sant’Orsola-Malpighi Polyclinic to present one abstract on AML patient stratification with the Open Microwell platform at the 58th ASH Annual Meeting

Bologna (Italy), 4 November 2016.

Cellply announced today that the results of a scientific collaboration with hematologists at Seragnoli Institute of Sant’Orsola Polyclinic in Bologna (Italy) working on Acute Myeloid Leukemia (AML), a group led by Prof. Giovanni Martinelli, will be presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH), on December 3-6 in San Diego, CA, USA. “This is a key milestone for our company as it shows the potential of the Open Microwell technology and the IVD platform under development at Cellply to become an important tool for guiding the identification of the appropriate treatment for each patient or patient set through the analysis of biological information that today remain mostly not exploited for patient stratification”, says Massimo Bocchi, CEO of Cellply. “The preliminary data collected within this scientific activity provided good correlation between our test and the clinical outcome, making Cellply’s platform promising for predicting the haematological response, an endpoint of primary importance not only from a clinical standpoint but also for its use within clinical trials”, added Laura Rocchi, Head of Biology at Cellply. The following abstract was accepted for poster presentation by the American Society of Hematology.

Title: Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform
Authors: Laura Rocchi, Andrea Faenza, Laura Rambelli, Viviana Guadagnuolo, Giovanni Marconi, Giorgia Simonetti, Cristina Papayannidis, Antonella Padella, Nicola Pecorari, Luca Giulianelli, Dario Biscarini, Giovanni Martinelli, Roberto Guerrieri and Massimo Bocchi
Abstract ID: 1675
Date/Time: Saturday, December 3, 2016, 5:30 PM-7:30 PM
Location: Hall GH (San Diego Convention Center)
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Link to abstract on Blood Journal

 

Cellply wins an H2020 SME Instrument Phase 1 grant

Bologna (Italy) – Bruxelles (Belgium), 20 October 2016

Cellply has recently been awarded by the European Commission as winner of a SME Intrsument Phase 1 grant within the Horizon 2020 programme. The ONCOSMART (ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics) project aims at developing an innovative platform for precision medicine, able to profile each cancer patient by analyzing how one or multiple candidate drugs interact with patient’s cells. The innovative test works by extracting a tumor sample and loading it in the platform readily after sampling, while cells are still alive. The ability of the drug to kill tumor cells is then analyzed and personalized response profiles are created. The platform, consisting of a lab-on-a-chip embedded in disposable cartridge, an analytical instrument and a diagnostic software, provides a result in 24 hours and aims at guiding clinicians in selecting the optimal therapy on a patient-by-patient basis and at supporting drug development companies during clinical development of new drugs. The project will allow Cellply to perform a feasibility study, explore business opportunities and regulatory issues/opportunities, identify a supply chain and set the basis for the development of a new in-vitro diagnostic (IVD) platform.